Within the immune system, interleukin-15 (IL-15) plays a relevant role by boosting the number of cytotoxic T cells and NK cells, the major drivers of anticancer immune response. Researchers from Sotio Biotech AS, MD Anderson and collaborators reported preclinical data on nanrilkefusp alfa (nanril; SOT-101), an IL-15 receptor βγ superagonist that stimulates both CD8+ T and NK cells in the tumor microenvironment.
Genescience Pharmaceuticals Co. Ltd. has prepared and tested new fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, osteochondrodysplasia and achondroplasia.
Work at the University of Florida has led to the identification of nuclear receptor subfamily 1 group D member 1 (Rev-erbA-α) antagonists reported to be useful for the treatment of cancer, sarcopenia and Duchenne muscular dystrophy.
Antibody-drug conjugates (ADCs) have demonstrated their effectiveness in a variety of solid tumors such as breast, lung, ovarian or bladder cancer and in hematological cancers too. However, in some cancer types, like pancreatic cancer, treatment with ADCs needs enhancement through more appropriate targets and payloads.
High-grade serous ovarian cancer (HGSC) is among the most lethal gynecologic malignancies, with up to 90% of patients eventually becoming resistant to platinum-based chemotherapy. The limited availability of effective targeted therapies for platinum-resistant HGSC presents a significant clinical challenge.
Researchers from Tango Therapeutics Inc. have unveiled DNA ligase 1 (LIG1) as a potential new therapeutic target for synthetic lethality in BRCA1-mutant cancers after CRISPR/Cas9 screening.
A recent study published in the Journal of Clinical Investigation by researchers at Johns Hopkins University School of Medicine and collaborators identified HMGA1 as a key epigenetic regulator that enhances Wnt signaling in colon cancer.
An Inventisbio Co. Ltd. and Inventisbio LLC patent discloses new phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS) and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities (CLOVES syndrome).
Asieris Pharmaceuticals Co. Ltd. has synthesized new protein arginine N-methyltransferase 5 (PRMT5) inhibitors described as potentially useful for the treatment of bladder cancer.